Improve Outcomes.
Reduce Adverse Events.
Lower Costs.

DoseMe is designed for healthcare
practitioners to improve patient care
by simplifying personalised dosing.

"What an amazing export.
Creating jobs."

— Prime Minister of Australia, Malcolm Turnbull,
with DoseMe founder Robert McLeay at
River City Labs conference June 2016.

DoseMe Voted #1
Most Opportunity for Global Expansion

DoseMe recognised at the inaugural 2016 Advance Queensland
Innovation and Investment Summit Gala as Qld startup with
the most global expansion opportunity.

(From Left: Queensland Treasurer, Hon Curtis Pitt; DoseMe Founder, Dr Robert McLeay; Queensland Premier, Hon Annastacia Palaszczuk)
--> Start Improving Patient Outcomes Now
Personalised Medicine: Making Complex Simple

DoseMe is easy-to-use software that allows clinicians to dose a patient based upon their ability to absorb, process, and clear a drug. Learn about the importance of individualised dosing by examining the impact of personalising dosing using DoseMe.

Improve Outcomes

Personalised dosing has been shown to be beneficial for drugs from antibiotics to chemotherapeutics to more. Learn more here.

Reduce Adverse Events

Dose-individualisation reduces adverse events, and has even been shown to halve side-effects in chemotherapy. See the research here.

Lower Costs

Personalised dosing has known and quantified cost-benefits, with up to a 52:1 cost-benefit ratio. View the studies here.

About DoseMe

DoseMe: Easy-To-Use Software

DoseMe is easy-to-use software that allows clinicians to dose a patient based upon that patient's individual ability to absorb, process, and clear a drug. DoseMe is CE marked for European use, and listed on the Australian Register of Therapeutic Goods. DoseMe is commercially available today for clinical use by healthcare professionals.

DoseMe supports clinical decision making in dosing a patient based upon that patient's individual ability to absorb, process, and clear a drug. Using more than basic patient information such as height, weight, and gender, DoseMe accurately calculates dosage based on the metabolism of individual patients - without requiring more laboratory tests than are currently performed. DoseMe learns how each patient responds to a drug - and continues to learn over time. By doing so, DoseMe provides true personalised medicine — and significantly improved dosing accuracy and patient outcomes.

Latest News and Updates

August 25, 2016

DoseMe completes Series A financing, eyes global expansion

Australian Financial Review reports DoseMe, a privately held digital medical solutions provider, today announced it closed a $2.6 million Series A financing round.

July 18, 2016

DoseMe Partners with Charm Health

Today DoseMe announced a strategic alliance with specialist oncology eHealth provider, Charm Health, to integrate its personalised dosing tool with the CHARM™ platform. This will provide clinicians using CHARM with immediate access to the DoseMe library of individualised dosing models, significantly enhancing their clinical decision-making in the complex area of dose adjustment of chemotherapy and other medicines used in cancer care.

July 12, 2016

2016 Queensland iAwards

DoseMe has won the Community Services category in the 2016 Queensland iAwards. This is the second iAwards win that DoseMe has achieved, taking out the start-up category in 2014 when DoseMe launched. We look forward to competing in the national round in September!

June 8, 2016

DoseMe Opens New Office In Brisbane

A great big thank you to Leeanne Enoch, QLD Minister for Science and Innovation for supporting our startup adventure and formally opening the new DoseMe premises in Taringa.

June 1, 2016

Malcolm Turnbull supports DoseMe on our quest to making personalised dosing simple!

At River City Labs on Wednesday, Prime Minister Malcolm Turnbull dropped in for a visit, and discussed DoseMe with our founder, Dr Robert McLeay. "An exporting business, taking Australian ideas to the world", was how Prime Minister Turnbull described DoseMe.

May 31, 2016

DoseMe's Founder to present at eHealth Qld Expo

DoseMe's Founder, Dr Robert McLeay, has been invited to speak at the inaugural eHealth Queensland Expo on how eHealth data can be used to improve patient outcomes via personalised medicine. We look forward to seeing you there!

May 20, 2016

Siemens Healthcare Partnership

DoseMe today has launched a partnership with Siemens at the GPCE Sydney conference to provide DoseMe alongside the Xprecia Stride™, Siemens' new point-of-care INR test device, into GP practices and other primary care facilities. By combining the intuitive and accurate Xprecia Stride with DoseMe, managing warfarin patients is quick and seamless, from testing through to dosing.

April 18, 2016

DoseMe wins best Queensland Start-up

At the Innovation and Investment Summit Gala Dinner, DoseMe was awarded as the best startup for global growth out of five advanced-stage startups presenting.

February 25, 2016

St. Vincent's Hospital Sydney Partnership

St. Vincent's Hospital Sydney have partnered with DoseMe for both clinical and research use. We look forward to supporting UNSW and St. Vincent's Hospital Sydney in this research focussing on improving the dosing of antimicrobials.

February 11, 2016

Apotex Partners as Exclusive Distributor

DoseMe is excited to partner with Apotex, Australia's largest generic drug company, as the exclusive Australian distributor of DoseMe to hospital pharmacies. We look forward to working together to improving dosing in Australian hospitals.

February, 2016

Android App Released

DoseMe has released an Android™ App - our first official support for the Android platform. We are committed to continuing to build upon and improve the DoseMe experience on Android.

Get it on Google Play

Partners and Customers